LifeScan (US) and Novo Nordisk (Denmark) managing diabetes together
This article was originally published in Clinica
Novo Nordisk (Denmark) and LifeScan (US) have signed a joint marketing deal to provide a total diabetes management service. The two companies will work together to market their complementary product lines - Novo's insulin and LifeScan's blood glucose monitoring systems. Johnson & Johnson subsidiary LifeScan sees the agreement as an opportunity to market its One Touch systems in international markets, particularly Europe and Japan.
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.